Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2001

View Archived Issues

AVI-4126 enters phase I/II study for polycystic kidney disease

Nastech's nasally administered apomorphine has excellent efficacy in erectile dysfunction Rx

XTL Biopharmaceuticals extends human lactoferrin research program with AM-Pharma

Nonapproval letter for GlaxoSmithKline's Augmentin XR extended-release tablets

FDA approval extends Paxil's indications to include posttraumatic stress disorder

Obesity drug ATL-962 completes phase I development program

Good progression reported in phase II trial of COLAL-PRED in ulcerative colitis

Approval recommended in E.U. for Arixtra

Preliminary interim results show no brown fat proliferation in Vasomax-treated rats

Promising pyrrolopyridine-substituted oxazolidinones characterized at ICAAC by R.W. Johnson

Millennium in-licenses novel oncology compounds from Xenova

Isis and Chiron enter target validation collaboration

BTG strengthens oncology portfolio through technology acquisition

Merck & Co. announces new pipeline candidates

Novel non-beta-lactam inhibitors of beta-lactamase under evaluation at MethylGene

GI-448, a novel macrolide with activity against resistant mycobacteria in vitro and in vivo

Ketolides designed at Abbott with excellent activity against resistant respiratory tract pathogens

ICAAC meeting selected by Shionogi to showcase a new, broad-spectrum parenteral cephalosporin

Major biotechnology merger in the making

Apoptosis inducers from Cytovia useful in the treatment of cancer

Novel macrocyclic compounds under development for use in HCV infection

Protease inhibitors disclosed by SuperGen and Wichita State

Synthesis and use of cyclohexylamine series of NMDA receptor antagonists

U.S. patent covers Guilford's metabotropic glutamate receptor ligands and their use

Ferring reports new compounds inhibiting DPP-IV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...